OWC Pharmaceutical Research (OTC:OWCP) has entered a $750,000 equity purchase agreement with Kodiak Capital Group.
As quoted in the press release:

Under the terms of the Agreement, OWC Pharmaceutical Research Corp (“OWC” or the “Company”) has the right to sell Kodiak$750,000 of OWC’s common stock. Kodiak cannot require OWC to sell shares to Kodiak, but is obligated to make purchases as requested by OWC. Proceeds from the financing will be utilized by OWC to further develop the Company’s proprietary cannabis-centric products and for working capital.

OWC Pharmaceutical Research Chairman, Mordechai Bignitz, said:

We are very excited to receive our first direct investment from an institution, especially one as respected as Kodiak Capital Group. This proves to us at OWC that we are on the right track with our vision for clinical research by Institutional Review Board-approved trials, which is the prime message for the future of the Medical Cannabis market.
There are a number of companies working on cannabinoid-based therapies, but OWC Pharmaceutical Research is one of only a few that are conducting trials in accordance with IRB. We believe that this strategy not only provides OWC with a distinct competitive advantage, but that it will also demonstrate that cannabis therapies can be just as effective, if not more effective, than industrial pharmaceuticals. We have been working vigorously to complete the delivery methodology and safety protocol for our multiple myeloma cannabis-based formulation so that we can begin clinical trials for efficacy. This funding from Kodiak will facilitate that effort

Click here for the full press release.

 Matica Enterprises Inc. (CSE: MMJ) (OTCQB: MMJFF) (FSE: 39N) (“Matica” or the “Company”) reports the Company has granted 6,500,000 stock options exercisable at $0.05 for five years from date of grant. These include 4,000,000 options to two officers (who are also directors) and, 2,500,000 to two consultants.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

Keep reading... Show less

The Company welcomes adult-use customers at its eight dispensaries across the state and will create 120 new jobs in surrounding communities

– Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced it will begin serving adult-use consumers across its eight dispensaries in Arizona .

Keep reading... Show less

Harvest Health & Recreation Inc. (“Harvest”) (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today announced the launch of recreational cannabis sales in Arizona .

Keep reading... Show less

Jason Mitchell Co-Founder, Director and Chief Executive Officer, HempFusion Wellness Inc. (“HempFusion” or the “Company”) (TSX: CBD.U), and his team joined David Chelich Sector Head, Global Energy and Diversified Industries, TMX Group, to celebrate the Company’s new listing on Toronto Stock Exchange and open the market.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

The Horizons Psychedelic Stock Index ETF index is expected to start trading on Tuesday, January 26, under the ticker PSYK on the NEO exchange.

Keep reading... Show less